McKesson/HBOC has filed a countersuit against shareholders who sued the company after its stock took a nosedive in mid-1999 (HNN 10/18/00). McKesson/HBOC stock lost $9 billion in value in one day after revelation of a financial scandal
McKesson/HBOC has filed a countersuit against shareholders who sued the company after its stock took a nosedive in mid-1999 (HNN 10/18/00). McKesson/HBOC stock lost $9 billion in value in one day after revelation of a financial scandal involving Albert Bergonzi and Jay Gilbertson, co-presidents and co-chief operating officers for HBOC before the merger of McKesson and HBOC.
The two men were indicted in October by the U.S. Securities and Exchange Commission on 17 counts of securities fraud, conspiracy, mail fraud, and wire fraud for falsifying company ledgers to boost HBOC profits prior to the merger in January 1999. When McKesson/HBOC announced in April 1999 that it would have to restate several years' worth of earnings reports, the company's stock fell from around $66 per share to $34.50 in one day. This prompted the shareholder lawsuit.
McKesson/HBOC's countersuit, however, alleges that stockholders were "unjustly enriched" before the stock crash and that the company was victimized as well. While the shareholder complaint claims that McKesson knew about HBOC's financial finagling before finalizing its purchase of HBOC, McKesson denies the charge.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
2 Commerce Drive
Cranbury, NJ 08512